ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 864,86
0,92%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Shuttle Pharmaceuticals Holdings Inc (SHPH)

  7. Shuttle Pharmaceuticals Holdings Inc (SHPH) Actualités

SHPH

Shuttle Pharmaceuticals (SHPH)

Shuttle Pharmaceuticals Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SHPH
DateHeureSourceTitreSymboleSociété
18/06/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
18/06/202415h00GlobeNewswire Inc.Shuttle Pharma Appoints Timothy Lorber as Chief Financial OfficerNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/06/202412h12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/05/202422h15GlobeNewswire Inc.Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/05/202415h00GlobeNewswire Inc.Shuttle Pharma Provides First Quarter 2024 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/05/202423h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/04/202422h15GlobeNewswire Inc.Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/03/202414h00PR Newswire (US)Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
09/03/202400h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/02/202414h00PR Newswire (US)Shuttle Pharma Announces Its Intent to Pursue a Rights OfferingNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/01/202422h30PR Newswire (US)Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/01/202415h00PR Newswire (US)Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/12/202315h00PR Newswire (US)Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/11/202315h00PR Newswire (US)Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
31/10/202314h00PR Newswire (US)Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202322h15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202322h10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/10/202315h00PR Newswire (US)Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
25/09/202315h00PR Newswire (US)Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/09/202315h00PR Newswire (US)Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health FairNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/09/202315h00PR Newswire (US)Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor PlatformNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
29/08/202315h00PR Newswire (US)Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer TherapeuticsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
24/08/202320h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
15/08/202315h00PR Newswire (US)Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
03/08/202315h00PR Newswire (US)Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical TrialNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
16/06/202312h31Edgar (US Regulatory)Information Statement - All Other (definitive) (def 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
05/06/202322h29Edgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
30/05/202323h31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202315h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202315h00PR Newswire (US)Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SHPH

Dernières Valeurs Consultées

BOV
CMCS34M
Comcast DRN MB
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés